IDP-023 + ocrelizumab + interleukin-2

This is a combination therapy consisting of **IDP-023 (g-NK cell therapy)**, **ocrelizumab**, and **interleukin-2**, investigated for multiple sclerosis, particularly primary progressive and non-active secondary progressive forms. - **IDP-023** is an allogeneic cell therapy utilizing g-NK (FcεR1γ-negative, CMV-induced natural killer) cells, which are thought to kill pathogenic human leukocyte antigen E (HLA-E) expressing autoreactive T and B cells involved in MS, and release more activating cytokines and cytolytic molecules compared to conventional NK cells. - **Ocrelizumab** is a recombinant humanized monoclonal IgG1 antibody targeting CD20, leading to B cell depletion primarily through antibody-dependent cellular cytotoxicity and complement-dependent cytolysis. - **Interleukin-2 (IL-2)** is a cytokine therapy that stimulates proliferation and activation of T lymphocytes and NK cells, supporting immune modulation and the expansion/function of infused g-NK cells. The combination is administered intravenously and aims to leverage cell-based cytotoxicity, B cell depletion, and enhanced immune stimulation for reducing disease activity in progressive MS. The therapy is being studied in multi-center dose escalation and expansion trials led by academic and industry collaboration[1][4][7].

Brand names

Ocrevus

Other names

g-NK cell therapyIL-2IL2IL 2